Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. - Wikidata - wikimedia - TriplyDB

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.

http://www.wikidata.org/entity/Q37355935

about

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.Safe use of proton pump inhibitors in patients with cirrhosis.

P2860

Q50057713-CB051572-D99E-44F3-A97A-25516BC5EC6C Q55718075-351B1153-A3C7-4E66-9BDB-FC00E927FA99

P2860

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.

http://www.wikidata.org/entity/Q37355935

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluating the safety and dosi ...... ure review and expert opinion.

@en

Evaluating the safety and dosi ...... ure review and expert opinion.

@nl

type

label

Evaluating the safety and dosi ...... ure review and expert opinion.

@en

Evaluating the safety and dosi ...... ure review and expert opinion.

@nl

prefLabel

Evaluating the safety and dosi ...... ure review and expert opinion.

@en

Evaluating the safety and dosi ...... ure review and expert opinion.

@nl

P1433

Q37355935-3FD254CA-0F58-410F-A67C-94037936BE82

P1476

Q37355935-40CE138E-9122-4F80-BCD6-47F18E77A405

P2093

Q37355935-01FF0596-052D-43C9-A187-A937D166DDCB

Q37355935-3C3CE76A-72C2-4A13-8EF7-C5D34EB3C4B8

Q37355935-8A637058-03FB-4C15-9283-BAB70CC6C9AE

Q37355935-9FAE2B9A-BCA3-4505-9275-F61D4CED3F59

Q37355935-A7FF93E9-A351-4F48-9E60-E99B378CB7A8

Q37355935-C1B90CC9-E946-4F33-9534-DFA94BF4285E

Q37355935-C85D98C8-0E84-4E83-9ABC-5A64DBE48176

Q37355935-F0FAACFE-CFED-495F-846C-2BB955566530

Q37355935-F67B0C8D-9F9D-4194-BCBB-CF632761DA8D

P275

Q37355935-B817CA4A-0317-464B-8BB8-B6048A0F5411

P2860

Q37355935-076C7168-C32C-4999-B6A5-7E14C7FD84FA

Q37355935-0A8F0A51-5EE5-40A8-94BE-D8E48CAEDB76

Q37355935-142C129C-6C83-4E9A-9EB5-B1409763884F

Q37355935-18BC669F-2460-4B8E-ADF5-674FE169B238

Q37355935-1BDFDEFD-1DD5-451D-BE06-79D45EBE130D

Q37355935-2433EBB2-9AC1-41D9-A604-CF78DAFB2D22

Q37355935-3F9828F7-019C-4F4B-856E-ABAE5CA0275C

Q37355935-48CEB829-4070-4F88-85BF-4636FCE3A06E

Q37355935-50515C92-00FF-4EF5-88A6-AF56B77C1B6D

Q37355935-543214F2-37C9-4EEE-9B86-027123E7196E

P304

Q37355935-4BFD79EB-C4E8-472B-A5D0-AFE1FF3E896F

P31

Q37355935-3ED9A75E-AE27-4920-B758-EA48C7EA2712

Q37355935-6F02997F-557F-4B4A-A2AB-8BDA1AE89F92

P356

Q37355935-A800257B-A686-4186-992A-F09B305CCC70

P433

Q37355935-F514E95A-7744-4A3D-9D90-7CBFDA4D27E7

P478

Q37355935-D0A014AE-EA74-4FBA-99D9-BABD1C0CADCA

P50

Q37355935-4BCB23B1-5E7C-40E6-A727-2FDE2552F656

Q37355935-F9C4D195-F86B-4A46-BC88-46DA84612827

P5008

Q37355935-0D1E2F8D-9B1B-420E-88E5-573ADF987FD9

P577

Q37355935-7661764D-4B17-4FBE-B6DC-2BDF0270D951

P698

Q37355935-3D455405-ED55-4A04-83C0-1E84A69CC91E

P921

Q37355935-1EBEC1E5-0037-437D-B1E3-2CA3B7114D0E

Q37355935-C0D1602E-018E-441A-905D-8A51A0157B68

P932

Q37355935-B098C699-4069-4009-9A43-7EEE4B02F083

P356

BMJOPEN-2016-012991

P1433

P1476

Evaluating the safety and dosi ...... ure review and expert opinion.

@en

P2093

David M Burger

http://www.w3.org/2001/XMLSchema#string

Herold J Metselaar

http://www.w3.org/2001/XMLSchema#string

Joost P H Drenth

http://www.w3.org/2001/XMLSchema#string

Margje H Monster-Simons

http://www.w3.org/2001/XMLSchema#string

Margriet Bouma

http://www.w3.org/2001/XMLSchema#string

Minke Kranenborg

http://www.w3.org/2001/XMLSchema#string

Nicole G M Hunfeld

http://www.w3.org/2001/XMLSchema#string

Sander D Borgsteede

http://www.w3.org/2001/XMLSchema#string

Sandra A W van Putten

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Dose adjustment in patients with liver disease

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

The burden of liver disease in Europe: a review of available epidemiological data.

Transection of the oesophagus for bleeding oesophageal varices.

Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.

Review article: prescribing medications in patients with cirrhosis - a practical guide.

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

P304

e012991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJOPEN-2016-012991

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Rianne A Weersink

P5008

P577

2016-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27733414

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

pharmaceutical preparation

P932

5073492

http://www.w3.org/2001/XMLSchema#string